PONATINIB 15 / 30 MG TABLETS
ICLUSIG (ponatinib) is a kinase inhibitor. Iclusig tablets are available as white, round, film-coated tablets for oral administration. Each tablet contains ponatinib hydrochloride equivalent to 15 or 45 mg ponatinib with the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate (type B), colloidal silicon dioxide, magnesium stearate and a tablet coating. The tablet coating consists of talc, polyethylene glycol, polyvinyl alcohol, and titanium dioxide.
ICLUSIG (ponatinib) 15mg & 45mg
"As per Recommendation by Company:
Ponatinib 45 mg taken orally once daily with or without food (2), Modify or interrupt dosing for hematologic and non-hematologic toxicity or AS Directed by the Treating Physicia"
"ICLUSIG(ponatinib) is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase
chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia
chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase
inhibitor therapy."